^
Association details:
| Biomarker: | RET exon 11 deletion |
|---|---|
| Cancer: | Thyroid Gland Medullary Carcinoma |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) + Zarnestra (tipifarnib) (CXCL12 inhibitor, Farnesyl transferase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib
Excerpt:
In summary, our patient with sporadic MTC and a novel, somatic deletion in exon 11 of the RET kinase gene showed a rapid and marked response to a regimen incorporating the RET kinase inhibitor sorafenib.
DOI:
10.1158/1535-7163.MCT-07-2422
